Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.

Journal of Cancer Research and Clinical Oncology
Nidhi SinghAnoop Saraya

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer. There are various sub-cellular events (both genetic and epigenetic) that get dysregulated leading to tumorigenesis. Methylation in promoters of tumor suppressor genes is one of these epigenetic phenomena contributing to the pathogenesis of cancer. Genes analyzed for promoter methylation status in this study namely SPARC (Secreted Protein Acidic and Rich in Cysteine, UCHL1 (ubiquitin carboxy-terminal hydrolase L1), NPTX2 (neuronal pentraxin 2), PENK (proenkephalin) had been studied in pancreatic cancer, but there is a need to check methylation in these genes as circulatory non-invasive markers. This study analyzed the absolute quantification of methylation levels of SPARC, UCHL1, PENK, and NPTX2 genes promoters in PDAC patients as well as in chronic pancreatitis (CP) patients and healthy subjects (HC) and evaluated its clinical significance in PDAC. The study included 65 PDAC patients, 25 CP patients, and 25 healthy controls. DNA was extracted from their plasma samples and subsequently given bisulfite treatment. Absolute quantization of methylated and unmethylated copies of gene promoters of all the four genes was performed using real-time PCR (SYBR green) by t...Continue Reading

References

Aug 1, 1985·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·B Mattsson, L E Rutqvist
Nov 1, 1995·Cancer·J E NiederhuberH R Menck
Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Feb 28, 2003·Molecular Cancer·Gunter Schneider, Roland M Schmid
Apr 4, 2003·Cancer Biology & Therapy·Sunil R Hingorani, David A Tuveson
Aug 15, 2003·World Journal of Gastroenterology : WJG·Li WangHui Li
Jan 21, 2004·Nature Reviews. Cancer·Andrew P Feinberg, Benjamin Tycko
Jun 22, 2005·Pancreas·Xiaozhong Guo, Zhongmin Cui
Jan 21, 2006·Cancer Research·Hiroyuki MatsubayashiMichael Goggins
May 9, 2008·Nature Reviews. Genetics·Miho M Suzuki, Adrian Bird
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Jul 31, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jun YuJoseph J Y Sung
Sep 30, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Seung-Mo HongMichael Goggins
Sep 16, 2009·Carcinogenesis·Shikhar SharmaPeter A Jones
Feb 18, 2010·Cell Cycle·Anjali BhedaJulia Shackelford
Apr 17, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lili LiYa Cao
May 9, 2012·World Journal of Gastroenterology : WJG·Ye ZhangYu Bai
Jan 31, 2013·The American Journal of the Medical Sciences·Fan YaoShubao Wang
Apr 5, 2013·World Journal of Gastroenterology : WJG·Norihiro KatoYasuhisa Shinomura
Apr 30, 2013·Gastroenterology·Dhiraj Yadav, Albert B Lowenfels
Jun 20, 2013·Gastroenterology Research and Practice·Lixin YangJiaming Qian
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joo Mi YiNita Ahuja
Oct 4, 2014·World Journal of Gastroenterology : WJG·Yi-Feng ZhouXiao-Feng Zhang
Jun 22, 2017·Journal of Cellular Biochemistry·Yanhong LuoHua Zhu

❮ Previous
Next ❯

Citations

Jun 12, 2020·International Journal of Molecular Sciences·Sona CiernikovaBozena Smolkova
Jan 17, 2021·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·L SivapalanC Chelala
Aug 28, 2021·Biomolecules·Sarah S WangChang-Il Hwang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.